Eyenovia, Inc. (NASDAQ:EYEN) Short Interest Down 41.4% in March

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 138,200 shares, a decrease of 41.4% from the February 28th total of 236,000 shares. Based on an average daily volume of 447,700 shares, the short-interest ratio is currently 0.3 days. Currently, 6.6% of the company’s shares are short sold.

Eyenovia Stock Down 10.3 %

EYEN traded down $0.13 during trading on Friday, hitting $1.13. The stock had a trading volume of 88,711 shares, compared to its average volume of 151,096. The stock has a 50 day simple moving average of $2.18 and a two-hundred day simple moving average of $16.56. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. Eyenovia has a twelve month low of $1.13 and a twelve month high of $124.80. The company has a market capitalization of $1.57 million, a PE ratio of -0.02 and a beta of 1.29.

Institutional Investors Weigh In On Eyenovia

An institutional investor recently raised its position in Eyenovia stock. Geode Capital Management LLC grew its stake in Eyenovia, Inc. (NASDAQ:EYEN) by 3.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 577,393 shares of the company’s stock after buying an additional 19,399 shares during the quarter. Geode Capital Management LLC owned 41.54% of Eyenovia worth $84,000 as of its most recent SEC filing. Institutional investors and hedge funds own 25.84% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating and issued a $2.00 target price on shares of Eyenovia in a report on Friday, March 21st.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.